Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

Eniu, Alexandru; Palmieri, Frances M.; Perez, Edith A.

doi:10.1634/theoncologist.10-9-665

Cited by 86 publications

(66 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several phase II studies (reviewed in Ref. [21]) have evaluated weekly paclitaxel in patients with MBC. This regimen was generally well tolerated with main toxicities being neutropenia and peripheral neuropathy.…”

Section: Discussionmentioning

confidence: 99%

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Fountzilas

Dafni

Dimopoulos

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Fountzilas

Dafni

Dimopoulos

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…7 Response rates of 25% to 69% have been reported when taxanes (paclitaxel or docetaxel) are used as ABC = ATP-binding cassette; BCRP = breast cancer resistance protein; CI = confidence interval; EGFR = epidermal growth factor receptor; FDA = Food and Drug Administration; HER2 = human epidermal growth factor receptor 2; IRR = independent radiology review; MBC = metastatic breast cancer; MDR = multidrug resistance protein; NCCN = National Comprehensive Cancer Network; ORR = overall response rate; OS = overall survival; PARP-1 = poly-ADP-ribose polymerase 1; PFS = progression-free survival; TN = triple negative; TTP = time to progression; VEGF = vascular endothelial growth factor first-line treatment of MBC. [8][9][10] In several phase 2 studies, Perez et al [11][12][13] demonstrated the activity and beneficial therapeutic ratio of weekly paclitaxel as a single agent or in combination with chemotherapy and biological therapy for MBC.…”

mentioning

confidence: 99%

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane

Moreno-Aspitia

Perez

2009

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common noncutaneous malignancy among every major ethnic group of women in the United States. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease. Moreover, even when these agents can be used in the metastatic setting, treatment failure occurs in most cases, and as a result the 5-year survival rates of patients with metastatic breast cancer are low. This outcome underscores the need for new, effective treatments of metastatic breast cancer and has led to investigation of novel ways to overcome the problem of drug resistance. This article reviews the current treatment options for breast cancer resistant to anthracycline and taxane and provides recommendations for disease management. Published sources for this review were found by searching PubMed (https://www.ncbi.nlm.nih.gov/pubmed) and congress Web sites.Mayo Clin Proc. 2009;84(6):533-545 B reast cancer is the most common noncutaneous malignancy among every major ethnic group of women in the United States, annually causing nearly 40,000 deaths in the United States and more than 400,000 deaths worldwide.1,2 Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents for treating breast cancer in hormone receptor-negative patients and those whose disease progresses while they are taking hormone therapy.3 These agents are commonly used in the adjuvant setting, either in combination or sequentially.4 A metaanalysis of 13 clinical trials involving nearly 23,000 women with high-risk, early-stage breast cancer showed that incorporating taxanes into anthracycline-based regimens significantly improves disease-free survival and overall survival (OS) rates. 5,6 This benefit is evident regardless of hormone receptor status, degree of nodal involvement, age, menopausal status, and type of taxane or administration schedule. Anthracyclines and taxanes, either alone or in combination, are also the preferred option for hormone receptor-negative patients with metastatic breast cancer (MBC). 7 Response rates of 25% to 69% have been reported when taxanes (paclitaxel or docetaxel) are used as ABC = ATP-binding cassette; BCRP = breast cancer resistance protein; CI = confidence interval; EGFR = epidermal growth factor receptor; FDA = Food and Drug Administration; HER2 = human epidermal growth factor receptor 2; IRR = independent radiology review; MBC = metastatic breast cancer; MDR = multidrug resistance protein; NCCN = National Comprehensive Cancer Network; ORR = overall response rate; OS = overall survival; PARP-1 = poly-ADP-ribose polymerase 1; PFS = progression-free survival; TN = triple negative; TTP = time to progression; VEGF = vascular endothelial growth factor

show abstract

“…Docetaxel is approved for use in breast (6,7), prostate (8,9), and nonsmall cell lung cancers (10, 11), and more recently head and neck cancer (12,13). Multiple previous studies have shown both the expression of HGF/SF and c-Met in these diseases (14 -17).…”

mentioning

confidence: 99%

AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

Jun

Sun

Rex

et al. 2007

Clinical Cancer Research

133

View full text Add to dashboard Cite

Purpose: Hepatocyte growth factor (HGF/SF) and its receptor c-Met have previously been shown to be up-regulated in multiple human cancers, including glioblastoma multiforme.To better understand if AMG102, a fully human, anti-HGF/SF^neutralizing antibody, could be incorporated into current clinical practice, AMG102 was tested preclinically in combination with temozolomide or docetaxel to determine if enhanced efficacy was observed compared with AMG102 alone. Experimental Design: The effects of AMG 102 were tested for antiproliferative activity in combination with temozolomide or docetaxel on U-87 MG cells in vitro and for antitumor activity in a U-87 MG xenograft model in vivo. Apoptotic activity was also measured for AMG 102 and docetaxel combined in vitro. Results: Treatment with temozolomide combined with AMG 102 resulted in increased inhibition of cell growth in vitro compared with treatment with either single agent alone. In U-87 MG xenografts in vivo, AMG 102 combined with temozolomide or docetaxel significantly increased the inhibitory effect on tumor growth when compared with treatment with either agent alone (P < 0.0001 and P < 0.015, respectively). In vitro, docetaxel alone induced both caspase-3/7 activity as well as poly(ADP)ribose polymerase and caspase-7 cleavage in U-87 MG cells; these events were enhanced when used in combination with AMG 102. Importantly, there was no evidence of interference between AMG 102 and either temozolomide or docetaxel in vitro or in vivo. Conclusion: These studies support testing of AMG 102 in combination with temozolomide or docetaxel. Such combinations may represent promising, novel clinical therapeutic strategies for cancers that are dependent on the HGF/SF/SF:c-Met pathway in the oncology setting.

show abstract

Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

Cited by 86 publications

References 80 publications

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane

AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

Contact Info

Product

Resources

About